Panelists discuss how differentiating primary from secondary erythrocytosis is crucial in guiding treatment strategies, emphasizing the importance of addressing underlying causes such as chronic ...

Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs), whether defined as lack of hemoglobin response to typical ESA doses or need for higher ESA doses to reach hemoglobi ...